CVRx is trading around $2.80, but the biggest catalyst may still be ahead.
Jorey Chernett, who owns more than 5.5% of CVRx, has already demanded that the Board begin a strategic alternatives review, with a sale of the company as the priority.
If CVRx announces that it has hired an independent financial advisor or investment bank to evaluate strategic alternatives, the market could immediately interpret this as a serious step toward a potential sale.
At $2.80, I believe the stock could easily 2x on that announcement alone — and potentially go much higher as investors begin speculating about strategic buyers.
The key question would no longer be: “Will CVRx be sold?”
It would be: “Who could be interested, and how much would they be willing to pay?”
With major MedTech companies potentially capable of creating significant additional value from Barostim, this could become a very different story very quickly.
$2.80 may be just the beginning.